Amgen

Open: 236.82 Close: 239.74 Change: 2.92

What an AI found about Amgen Company Inc Stock after reading the whole Internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, revenue, Program, year, CoPay, report, cost, and the most common words in the summary are: amgen, stock, inc, market, price, amgn, news, . One of the sentences in the summary was: Amgen expects full-year earnings in the range of $17.60 to $18.70 per share. Other …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen expects full-year earnings in the range of $17.60 to $18.70 per share. Both trials involving two different molecules were stopped for futility.

Today's News

Amgen reported revenue of $6.11 billion for the quarter, down 2% from a year earlier, but close to analysts estimates. Operating expenses increased 6%, research and development costs rose 12% and Amgen said its tax rate rose. Amgen to Present at the 43rd Annual TD Cowen Healthcare Conference 3/3/2023 Amgen will present at the 2023 TD Cowan Healthcare Conference at 11:10 a.m. Both trials involving two different molecules were stopped for futility, Amgen disclosed in its quarterly report. The Supreme Court will consider patent laws “enablement” requirement, in Amgen Inc. Supreme Court. Amgen stock (NASDAQ: AMGN) has seen a substantial 23% rise this year, far better than the broader S&P500 index, which is down 16%. Amgen expects full-year earnings in the range of $17.60 to $18.70 per share. Amgen shares have fallen 8.5% since the beginning of the year. Amgen raised 2023 revenue, eps outlook. Amgen previously forecast revenue of $26 billion to $27.2billion. Amgen Inc. filed for Patent in the U.S. and Puerto Rico in February 2023. If you purchased Amgen securities during the Class Period you may be entitled to compensation. Amgen SupportPlus Co-Pay Program helps eligible patients lower their out-of-pocket costs. Amgen First STEP ™, Prolia ™ ,EVENITY ™ and AVSOLA Co-Pay Programs are now combined into one Amgen supportPlus program. The program is open to patients with commercial insurance that covers the products listed above. The Amgen SupportPlus Co-Pay Card helps eligible patients cover out-of-pocket medication costs related to an Amgen supportPlus product, up to program limits. Program coverage is contingent on submission of the required Explanation of Benefits (EOB) form. Program coverage through the Amgen SupportPlus Co-Pay Card is contingent on the submission of the required Explanation of Benefits (EOB) form within 180 days of the date of approval documented on the EOB for medical benefit claims. Maximum Program Benefit, Patient Total Program Benefit and Benefits May Change, End or Vary Without Notice. Bernstein Liebhard LLP reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit against Amgen inc. (NASdaq: amgn) Amgen stock has declined 3.3% in the past year compared with a decrease of 9.2% for the industry. Product sales are expected to have been flat from the prior-year levels, while other revenues are expected lower on a year-over-year basis. Amgen Inc. reported Q1 FY23 sales of $6.11 billion, down 2% Y/Y, resulting from lower revenue from COVID-19 manufacturing collaboration, partially. The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations. Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, revenue, Program, year, CoPay, report, cost, and the most common words in the summary are: amgen, stock, inc, market, price, amgn, news, . One of the sentences in the summary was: Amgen expects full-year earnings in the range of $17.60 to $18.70 per share. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #inc #market #price #amgn #news.